Scarica l'app Stockscreener
6.75
4.01%
0.26
Pre-mercato:
6.66
-0.09
-1.33%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CAMP Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$6.49
Aprire:
$6.3
Volume 24 ore:
562.06K
Relative Volume:
3.41
Capitalizzazione di mercato:
$316.45M
Reddito:
$264.74M
Utile/perdita netta:
$-49.71M
Rapporto P/E:
-1.648
EPS:
-4.0959
Flusso di cassa netto:
$-43.55M
1 W Prestazione:
+84.93%
1M Prestazione:
+64.63%
6M Prestazione:
+338.31%
1 anno Prestazione:
-11.53%
Intervallo 1D:
$6.01
$6.86
Intervallo di 1 settimana:
$3.43
$6.86
Portata 52W:
$1.305
$7.79
Camp 4 Therapeutics Corp Stock (CAMP) Company Profile
Nome
Camp 4 Therapeutics Corp
Settore
Industria
Telefono
617-651-8867
Indirizzo
ONE KENDALL SQUARE, CAMBRIDGE, CA
Confronta CAMP con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CAMP
Camp 4 Therapeutics Corp
|
6.75 | 304.26M | 264.74M | -49.71M | -43.55M | -4.0959 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.71 | 114.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.62 | 77.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
850.95 | 54.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.50 | 52.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
196.92 | 42.02B | 447.02M | -1.18B | -906.14M | -6.1812 |
Camp 4 Therapeutics Corp Stock (CAMP) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-02 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-09-16 | Downgrade | JP Morgan | Overweight → Neutral |
| 2025-05-27 | Iniziato | Wedbush | Outperform |
| 2024-11-05 | Iniziato | JP Morgan | Overweight |
| 2024-11-05 | Iniziato | Piper Sandler | Overweight |
| 2024-11-05 | Iniziato | William Blair | Outperform |
| 2022-08-16 | Aggiornamento | Craig Hallum | Hold → Buy |
| 2021-12-22 | Downgrade | Craig Hallum | Buy → Hold |
| 2021-09-24 | Reiterato | Craig Hallum | Buy |
| 2021-06-25 | Reiterato | Craig Hallum | Buy |
| 2020-12-18 | Downgrade | JP Morgan | Neutral → Underweight |
| 2020-04-17 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-03-05 | Reiterato | Craig Hallum | Buy |
| 2019-12-20 | Reiterato | Craig Hallum | Buy |
| 2019-12-20 | Downgrade | First Analysis Sec | Outperform → Neutral |
| 2019-06-28 | Aggiornamento | Northland Capital | Market Perform → Outperform |
| 2019-05-29 | Downgrade | Goldman | Neutral → Sell |
| 2019-05-01 | Reiterato | Craig Hallum | Buy |
| 2019-03-25 | Downgrade | JP Morgan | Overweight → Neutral |
| 2019-01-25 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2018-12-21 | Aggiornamento | Craig Hallum | Hold → Buy |
| 2018-12-14 | Reiterato | B. Riley FBR | Buy |
| 2018-12-11 | Downgrade | First Analysis Sec | Strong Buy → Outperform |
| 2018-12-11 | Downgrade | Northland Capital | Outperform → Market Perform |
| 2018-11-27 | Iniziato | Goldman | Neutral |
| 2018-10-15 | Iniziato | Jefferies | Hold |
| 2018-09-28 | Reiterato | Craig Hallum | Hold |
| 2018-04-27 | Reiterato | Craig Hallum | Hold |
| 2018-03-08 | Downgrade | Craig Hallum | Buy → Hold |
| 2018-02-16 | Aggiornamento | First Analysis Sec | Equal-Weight → Overweight |
Mostra tutto
Camp 4 Therapeutics Corp Borsa (CAMP) Ultime notizie
CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Cantor Fitzgerald reiterates Overweight rating on CAMP4 Therapeutics stock By Investing.com - Investing.com Australia
CAMP4 Therapeutics Corporation (CAMP) Slides 6% in Pre-market: Without a Fresh Catalyst - Stocks Telegraph
Cantor Fitzgerald reiterates Overweight rating on CAMP4 Therapeutics stock - Investing.com India
Following a 46% Decline Over Last Year, Recent Gains May Please Camp4 Therapeutics Corporation (NASDAQ:CAMP) Institutional Owners - 富途牛牛
After losing 46% in the past year, Camp4 Therapeutics Corporation (NASDAQ:CAMP) institutional owners must be relieved by the recent gain - simplywall.st
Positive week for Camp4 Therapeutics Corporation (NASDAQ:CAMP) institutional investors who lost 46% over the past year - Yahoo Finance
Camp4 Therapeutics (CAMP) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Will Camp4 Therapeutics Corporation stock outperform international peersJuly 2025 Technicals & Expert-Curated Trade Recommendations - moha.gov.vn
How Camp4 Therapeutics Corporation stock valuations compare to rivals2025 Geopolitical Influence & Safe Entry Zone Identification - BỘ NỘI VỤ
CAMP4 Therapeutics Corporation (CAMP) -6.6% in After-hours: Without a Clear Catalyst - Stocks Telegraph
Activity Recap: How Camp4 Therapeutics Corporation stock valuations compare to rivalsQuarterly Growth Report & Free Daily Entry Point Trade Alerts - BỘ NỘI VỤ
[424B3] Camp4 Therapeutics Corp Prospectus Filed Pursuant to Rule 424(b)(3) - Stock Titan
How Camp4 Therapeutics Corporation stock performs in interest rate cyclesEntry Point & Safe Entry Zone Tips - newser.com
Will Camp4 Therapeutics Corporation stock split again soonQuarterly Portfolio Report & Long-Term Investment Growth Plans - newser.com
Chart based exit strategy for Camp4 Therapeutics CorporationQuarterly Market Review & Precise Trade Entry Recommendations - newser.com
Best data tools to analyze Camp4 Therapeutics Corporation stock2025 Technical Overview & Reliable Breakout Forecasts - newser.com
Will earnings trigger a reversal in Camp4 Therapeutics Corporation2025 Price Targets & Free Real-Time Volume Trigger Notifications - newser.com
Can Camp4 Therapeutics Corporation stock withstand economic slowdownTrade Risk Assessment & Long-Term Safe Investment Ideas - newser.com
Will Camp4 Therapeutics Corporation stock reach Wall Street targets2025 Retail Activity & Reliable Volume Spike Trade Alerts - newser.com
CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Camp4 Therapeutics to offer up to $300 million in securitiesSEC filing - marketscreener.com
Real time breakdown of Camp4 Therapeutics Corporation stock performance2025 Volume Leaders & Accurate Technical Buy Alerts - newser.com
Strategic Focus and Financial Strength Drive Buy Rating for CAMP4 Therapeutics - TipRanks
CAMP4 Reports Third Quarter 2025 Financial Results and Corporate Highlights - The Manila Times
Will Camp4 Therapeutics Corporation stock benefit from upcoming earnings reportsQuarterly Market Review & AI Forecasted Stock Moves - Fundação Cultural do Pará
How moving averages guide Camp4 Therapeutics Corporation tradingQuarterly Portfolio Summary & AI Enhanced Execution Alerts - newser.com
Does Camp4 Therapeutics Corporation qualify in momentum factor screeningQuarterly Profit Review & Long Hold Capital Preservation Plans - newser.com
How Camp4 Therapeutics Corporation stock trades before earningsMarket Movement Recap & Long-Term Investment Growth Plans - newser.com
Risk adjusted return profile for Camp4 Therapeutics Corporation analyzedJuly 2025 Levels & Verified Chart Pattern Trade Signals - newser.com
Can Camp4 Therapeutics Corporation stock sustain revenue growthTrade Entry Summary & Proven Capital Preservation Methods - newser.com
Is Camp4 Therapeutics Corporation stock overvalued by current metricsPortfolio Profit Report & Community Verified Watchlist Alerts - Fundação Cultural do Pará
How Camp4 Therapeutics Corporation stock reacts to global recession fearsLayoff News & Smart Swing Trading Techniques - newser.com
Can Camp4 Therapeutics Corporation stock weather global recessionGap Up & Safe Swing Trade Setups - newser.com
Can Camp4 Therapeutics Corporation stock reach $100 price targetCEO Change & Low Risk High Win Rate Picks - newser.com
What to do if you’re stuck in Camp4 Therapeutics CorporationWeekly Gains Summary & Smart Money Movement Alerts - newser.com
How to interpret RSI for Camp4 Therapeutics Corporation stockJuly 2025 Rallies & High Yield Stock Recommendations - newser.com
Volume spikes in Camp4 Therapeutics Corporation stock – what they meanStop Loss & High Accuracy Swing Entry Alerts - newser.com
Published on: 2025-10-19 02:06:54 - nchmf.gov.vn
Is Camp4 Therapeutics Corporation stock a safe buy before earningsJuly 2025 Recap & Weekly Momentum Picks - Trung tâm Dự báo KTTV quốc gia
Can Camp4 Therapeutics Corporation stock sustain market leadershipInflation Watch & Stock Portfolio Risk Control - nchmf.gov.vn
Camp 4 Therapeutics Corp Azioni (CAMP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Camp 4 Therapeutics Corp Azioni (CAMP) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Polaris Management Co. VII, L. | 10% Owner |
Sep 11 '25 |
Buy |
1.53 |
1,307,189 |
1,999,999 |
2,825,500 |
| Nashat Amir | Director |
Sep 11 '25 |
Buy |
1.53 |
1,307,189 |
1,999,999 |
2,825,500 |
| Maricich Yuri | Chief Medical Officer |
Sep 11 '25 |
Buy |
1.65 |
6,060 |
9,999 |
6,060 |
| Gold Kelly | Chief Financial Officer |
Sep 11 '25 |
Buy |
1.65 |
6,060 |
9,999 |
67,877 |
| Mandel-Brehm Josh | Chief Executive Officer |
Sep 11 '25 |
Buy |
1.65 |
6,060 |
9,999 |
278,417 |
| Young Richard A | Director |
Sep 11 '25 |
Buy |
1.65 |
15,151 |
24,999 |
170,010 |
0.36%
1.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):